SV2 (Synaptic Vesicle Protein 2) is expressed in neurons and endocrine cells where it is required for normal calcium-evoked neurosecretion. In mammals, there are three SV2 genes, denoted SV2A, B and C. SV2A interacts with synaptotagmin, the prime candidate for the calcium sensor in exocytosis. Here, we report that all isoforms of native SV2 bind synaptotagmin and that binding is inhibited by calcium, indicating that all isoforms contain a common calcium-inhibited synaptotagmin-binding site. The isolated amino termini of SV2A and SV2C supported an additional interaction with synaptotagmin, and binding at this site was stimulated by calcium. The amino-terminal binding site was mapped to the first 57 amino acids of SV2A, and removal of this domain decreased calcium-mediated inhibition of binding to synaptotagmin, suggesting that it modulates calcium's effect on the SV2-synaptotagmin interaction. Introduction of the amino terminus of SV2A or SV2C into cultured superior cervical ganglion neurons inhibited neurotransmission, whereas the amino terminus of SV2B did not. These observations implicate the SV2-synaptotagmin interaction in regulated exocytosis and suggest that SV2A and SV2C, via their additional synaptotagmin binding site, function differently than SV2B.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mcn.2004.12.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants.
Nat Struct Mol Biol
December 2024
Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Epilepsy is a common neurological disorder characterized by abnormal activity of neuronal networks, leading to seizures. The racetam class of anti-seizure medications bind specifically to a membrane protein found in the synaptic vesicles of neurons called synaptic vesicle protein 2 (SV2) A (SV2A). SV2A belongs to an orphan subfamily of the solute carrier 22 organic ion transporter family that also includes SV2B and SV2C.
View Article and Find Full Text PDFStructural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2.
Nat Commun
April 2023
Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, 92697, USA.
Botulinum neurotoxin E (BoNT/E) is one of the major causes of human botulism and paradoxically also a promising therapeutic agent. Here we determined the co-crystal structures of the receptor-binding domain of BoNT/E (HE) in complex with its neuronal receptor synaptic vesicle glycoprotein 2A (SV2A) and a nanobody that serves as a ganglioside surrogate. These structures reveal that the protein-protein interactions between HE and SV2 provide the crucial location and specificity information for HE to recognize SV2A and SV2B, but not the closely related SV2C.
View Article and Find Full Text PDFStructural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
Chem Biol Interact
March 2023
University of Aix-Marseille and INSERM U_1072, Marseille, France.
Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human. BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane. Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
View Article and Find Full Text PDFExpression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
Mol Brain
May 2022
Neurobiology Research Unit 8057, Neurological Clinic, Copenhagen University Hospital, Rigshospitalet, 6-8 Inge Lehmanns Vej, 2100, Copenhagen, Denmark.
Synaptic vesicle glycoprotein-2 (SV2) is a family of proteins consisting of SV2A, SV2B, and SV2C. This protein family has attracted attention in recent years after SV2A was shown to be an epileptic drug target and a perhaps a biomarker of synaptic density. So far, the anatomical localization of these proteins in the rodent and human brain have been reported, but co-expression of SV2 genes on a cellular level, their expressions in the human brain, comparison to radioligand binding, any possible regulation in epilepsy are not known.
View Article and Find Full Text PDFThe distribution of neuromuscular junctions depends on muscle pennation, when botulinum neurotoxin receptors and SNAREs expression are uniform in the rat.
Toxicon
June 2022
IPSEN Innovation, Les Ulis/Saclay, France. Electronic address:
Article Synopsis
- Botulinum neurotoxins (BoNTs) are used to help with muscle problems, but scientists need more info about how they work in different muscles.
- In a study with rats, researchers looked at how BoNT receptors are spread out in various muscles and found differences based on muscle shape.
- The findings could help doctors understand how to better use BoNT treatments in humans by showing where these receptors are located in our muscles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!